|
Name |
gibberellin A24(2-)
|
Molecular Formula | C20H24O5-2 | |
IUPAC Name* |
(1R,2S,3S,4R,8R,9R,12R)-8-formyl-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylate
|
|
SMILES |
C[C@]1(CCC[C@@]2([C@@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)[O-])C=O)C(=O)[O-]
|
|
InChI |
InChI=1S/C20H26O5/c1-11-8-20-9-12(11)4-5-13(20)19(10-21)7-3-6-18(2,17(24)25)15(19)14(20)16(22)23/h10,12-15H,1,3-9H2,2H3,(H,22,23)(H,24,25)/p-2/t12-,13+,14-,15-,18-,19-,20+/m1/s1
|
|
InChIKey |
QQRSSHFHXYSOMF-CXXOJBQZSA-L
|
|
Synonyms |
gibberellin A24(2-); GA24; CHEBI:143957; (1R,2S,3S,4R,8R,9R,12R)-8-formyl-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylate
|
|
CAS | NA | |
PubChem CID | 25246232 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 344.4 | ALogp: | 3.6 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 97.3 | Aromatic Rings: | 4 |
Heavy Atoms: | 25 | QED Weighted: | 0.559 |
Caco-2 Permeability: | -5.861 | MDCK Permeability: | 0.00001410 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.018 | 20% Bioavailability (F20%): | 0.601 |
30% Bioavailability (F30%): | 0.036 |
Blood-Brain-Barrier Penetration (BBB): | 0.836 | Plasma Protein Binding (PPB): | 66.32% |
Volume Distribution (VD): | 0.255 | Fu: | 24.32% |
CYP1A2-inhibitor: | 0.004 | CYP1A2-substrate: | 0.148 |
CYP2C19-inhibitor: | 0.01 | CYP2C19-substrate: | 0.079 |
CYP2C9-inhibitor: | 0.01 | CYP2C9-substrate: | 0.224 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.112 |
CYP3A4-inhibitor: | 0.145 | CYP3A4-substrate: | 0.026 |
Clearance (CL): | 0.788 | Half-life (T1/2): | 0.777 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.137 |
Drug-inuced Liver Injury (DILI): | 0.783 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.195 | Maximum Recommended Daily Dose: | 0.184 |
Skin Sensitization: | 0.757 | Carcinogencity: | 0.337 |
Eye Corrosion: | 0.886 | Eye Irritation: | 0.952 |
Respiratory Toxicity: | 0.885 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002556 | 0.773 | D0I1LH | 0.273 | ||||
ENC002555 | 0.590 | D0X7HM | 0.247 | ||||
ENC002558 | 0.462 | D0X4RS | 0.235 | ||||
ENC002554 | 0.457 | D02CJX | 0.233 | ||||
ENC000794 | 0.426 | D0IX6I | 0.230 | ||||
ENC002541 | 0.381 | D0KR5B | 0.230 | ||||
ENC001071 | 0.364 | D0I2SD | 0.225 | ||||
ENC003145 | 0.363 | D0V2JK | 0.224 | ||||
ENC002542 | 0.360 | D0Y3ME | 0.224 | ||||
ENC003143 | 0.315 | D08TEJ | 0.223 |